XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
C
C

Cigna

Yangiliklar

Reuters - 1 kun oldin

CVS Health rises as TD Cowen upgrades to "buy" on Medicare optimism

BUZZ-CVS Health rises as TD Cowen upgrades to "buy" on Medicare optimism ** Shares of CVS Health Corp CVS.N rise 3.1% to a near five-month high of $64.87 ** Brokerage TD Cowen upgrades stock to "buy" from "hold" and hikes PT to $85 from $59 - which represents a 35% upside to stock's last close ** Brokerage says it is confident in CVS achieving doub
C
Reuters - 2 kun oldin

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

UPDATE 1-Texas attorney general sues insulin makers and pharmacy middlemen over high costs Adds OptumRx, Cigna and Sanofi responses in paragraphs 11-15 Oct 3 (Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of collaborating to inflate the cost of insulin. Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly LLY.N , Novo Nordisk NOVOb.CO and Sanofi SASY.PA .
C
S
Reuters - 2 kun oldin

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

Texas attorney general sues insulin makers and pharmacy middlemen over high costs Oct 3 (Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of collaborating to inflate the cost of insulin. Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly LLY.N , Novo Nordisk NOVOb.CO and Sanofi SASY.PA .
C
S
Reuters - 2 kun oldin

Texas Attorney General Ken Paxton Sues Pharma Drug Manufacturers & Pharmacy Benefit Managers For "Conspiracy" That Increased Insulin Prices By 1,000%

BRIEF-Texas Attorney General Ken Paxton Sues Pharma Drug Manufacturers & Pharmacy Benefit Managers For "Conspiracy" That Increased Insulin Prices By 1,000% Oct 3 (Reuters) - Texas Attorney General Ken Paxton: TEXAS ATTORNEY GENERAL KEN PAXTON: SUES PHARMA DRUG MANUFACTURERS & PHARMACY BENEFIT MANAGERS FOR "CONSPIRACY" THAT INCREASED INSULIN PRICES
C
Reuters - 3 kun oldin

Humana slips as members in Medicare Advantage plans fall for 2025

BUZZ-Humana slips as members in Medicare Advantage plans fall for 2025 Updates ** Shares of health insurer Humana HUM.N fall as much as 23.7% to an over 4-year low of $213.31 ** Company says total members enrolled in its highly rated Medicare Advantage (MA) plans for people aged 65 years and above have reduced for 2025 ** HUM has about 1.6 mln, or 25%, of its members currently enrolled in plans rated 4 stars and above for 2025, down from 94% in 2024 ** Brokerage Evercore ISI says the news is pos
C
Reuters - 3 kun oldin

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W
Reuters - 3 kun oldin

CVS surgery would provide little if any relief

RPT-BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W
Reuters - 4 kun oldin

CVS surgery would provide little if any relief

BREAKINGVIEWS-CVS surgery would provide little if any relief The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Oct 1 (Reuters Breakingviews) - It’s easier to diagnose what ails CVS Health CVS.N than it is to prescribe a cure. Multiple profit warnings from the $78 billion healthcare conglomerate have raised doubts about its strategy.
A
C
W
Reuters - 4 kun oldin

CVS explores options including potential break-up, sources say

RPT-EXCLUSIVE-CVS explores options including potential break-up, sources say Adds background and details on CVS from paragraph 11 onwards By Anirban Sen NEW YORK, Sept 30 (Reuters) - CVS Health CVS.N is exploring options that could include a break-up of the company to separate its retail and insurance units, as the struggling healthcare services company looks to turn around its fortunes amid pressure from investors, people familiar with the matter told Reuters.
C
Reuters - 4 kun oldin

Health insurers unveil Medicare Advantage plans for 2025

UPDATE 2-Health insurers unveil Medicare Advantage plans for 2025 Adds details on UnitedHealth's plans in paragraphs 10 and 11 Oct 1 (Reuters) - Health insurers Cigna CI.N , CVS Health CVS.N , Humana HUM.N Centene CNC.N and UnitedHealth UNH.N on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above.
C
Reuters - 4 kun oldin

CVS, Cigna unveil Medicare Advantage plans for 2025

CVS, Cigna unveil Medicare Advantage plans for 2025 Oct 1 (Reuters) - CVS Health CVS.N and Cigna CI.N on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above , saying some members would pay $0 premium monthly for prescription drugs. The announcements come ahead of the beginning of enrollment for Medicare Advantage plans on October 15, which will continue through December 7. Medicare Advantage plans are offered by private insurers w
C
Reuters - 5 kun oldin

CVS explores options including potential break-up, sources say

EXCLUSIVE-CVS explores options including potential break-up, sources say Adds background and details on CVS from paragraph 11 onwards By Anirban Sen NEW YORK, Sept 30 (Reuters) - CVS Health CVS.N is exploring options that could include a break-up of the company to separate its retail and insurance units, as the struggling healthcare services company looks to turn around its fortunes amid pressure from investors, people familiar with the matter told Reuters.
C
Reuters - 2 hafta oldin

US Senator Sanders says middlemen won't punish Novo if it cuts weight-loss drug prices

UPDATE 4-US Senator Sanders says middlemen won't punish Novo if it cuts weight-loss drug prices Adds Lilly background in paragraph 7, CEO comment on working with PBMs, paragraph 11 By Ahmed Aboulenein and Patrick Wingrove WASHINGTON, Sept 24 (Reuters) - U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand coverage of Novo Nordisk's NOVOb.CO popular diabetes and weight-loss medicines if the company lowered the list p
C
Reuters - 2 hafta oldin

What to Watch in the Day Ahead - Tuesday, September 24

What to Watch in the Day Ahead - Tuesday, September 24 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Federal Reserve Board Governor Michelle Bowman is slated to speak on the economic outlook and monetary policy before the Kentucky Bankers Association Annual Convention in Virginia.
C
Reuters - 2 hafta oldin

Why are US pharmacy benefit managers under fire?

EXPLAINER-Why are US pharmacy benefit managers under fire? By Ahmed Aboulenein WASHINGTON, Sept 20 (Reuters) - The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.
C
Reuters - 2 hafta oldin

US FTC sues drug 'gatekeepers' over high insulin prices

UPDATE 3-US FTC sues drug 'gatekeepers' over high insulin prices Adds outside comment in paragraphs 6-7, drug company comment in paragraph 18, investor comment in paragraphs 21-22 By Jody Godoy and Ahmed Aboulenein Sept 20 (Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
C
S
Reuters - 2 hafta oldin

US FTC sues drug 'gatekeepers' over high insulin prices

US FTC sues drug 'gatekeepers' over high insulin prices By Jody Godoy and Ahmed Aboulenein Sept 20 (Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetic patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
C
S
Reuters - 3 hafta oldin

U.S. STOCKS AppLovin, Regal Rexnord, Talkspace

BUZZ-U.S. STOCKS ON THE MOVE- AppLovin, Regal Rexnord, Talkspace Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes rose on Tuesday, with the S&P 500 hitting an intraday record high ahead of a crucial Federal Reserve interest-rate decision, after fresh economic data allayed worries of a sharp slowdown in the U.S.
A
C
I
M
N
S
U
U
D
Reuters - 3 hafta oldin

Express Scripts sues FTC over drug pricing report, court documents show

UPDATE 2-Express Scripts sues FTC over drug pricing report Adds detail from the complaint and FTC comment in paragraphs 4-8, updates headline, byline and dateline By Jody Godoy NEW YORK, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts sued the U.S. Federal Trade Commission on Tuesday over the regulator's recent drug pricing report , calling the report's conclusion that the prescription middlemen raise drug costs defamatory.
C
Reuters - 3 hafta oldin

Express Scripts sues FTC over drug pricing report, court documents show

Express Scripts sues FTC over drug pricing report, court documents show WASHINGTON, Sept 17 (Reuters) - Pharmacy benefit manager Express Scripts has sued the U.S. Federal Trade Commission over the regulator's recent drug pricing report , asking a court to force the agency to withdraw its findings, according to court documents filed on Tuesday. Repo
C

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.